ImmuCell (NASDAQ:ICCC) Stock Price Passes Above 200 Day Moving Average – Here’s What Happened

Shares of ImmuCell Corporation (NASDAQ:ICCC) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $6.95 and traded as high as $9.80. ImmuCell shares last traded at $9.77, with a volume of 17,969 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Monday, April 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, ImmuCell presently has a consensus rating of “Sell”.

ImmuCell Trading Up 0.7%

The company’s 50 day simple moving average is $8.47 and its 200-day simple moving average is $6.95. The company has a quick ratio of 2.60, a current ratio of 4.82 and a debt-to-equity ratio of 0.24. The firm has a market cap of $88.42 million, a P/E ratio of -162.81 and a beta of 0.55.

ImmuCell (NASDAQ:ICCC) last posted its quarterly earnings results on Thursday, May 14th. The biotechnology company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.16. ImmuCell had a negative net margin of 1.82% and a negative return on equity of 1.88%. The firm had revenue of $10.36 million during the quarter, compared to the consensus estimate of $5.40 million.

Institutional Trading of ImmuCell

Several institutional investors and hedge funds have recently modified their holdings of ICCC. Militia Capital Management LLC bought a new stake in shares of ImmuCell during the first quarter valued at approximately $114,000. Steadtrust LLC purchased a new position in ImmuCell during the third quarter valued at approximately $198,000. Mesirow Financial Investment Management Inc. increased its holdings in ImmuCell by 199.6% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after buying an additional 24,303 shares during the period. Dimensional Fund Advisors LP increased its holdings in ImmuCell by 3.2% during the first quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 1,749 shares during the period. Finally, Geode Capital Management LLC grew its holdings in ImmuCell by 4.2% in the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after purchasing an additional 2,907 shares during the last quarter. Institutional investors own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.